Related references
Note: Only part of the references are listed.943b Induction Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial
B.G. Feagan et al.
GASTROENTEROLOGY (2015)
Su2082 Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Amg 181, a Fully Human Anti-α4β7 Antibody for Treating Inflammatory Bowel Diseases (IBD)
Wei-Jian Pan et al.
GASTROENTEROLOGY (2015)
Sa2025 Etrolizumab-Mediated Ex Vivo Modulation of Beta7 Cell Surface Receptors in Nonhuman Primate and Human Peripheral Blood Supports the Proposed Mechanism of Action
Marna Williams et al.
GASTROENTEROLOGY (2015)
Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates
Eric R. Fedyk et al.
INFLAMMATORY BOWEL DISEASES (2012)
Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study
Asit Parikh et al.
INFLAMMATORY BOWEL DISEASES (2012)
P019 Internalization of the vedolizumab/α4β7 complex and kinetics of restoring functional activity
L.-L. Yang et al.
Journal of Crohns & Colitis (2012)
A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes
E. G. Stefanich et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study
Severine Vermeire et al.
GUT (2011)
Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis
Saskia Thomas et al.
INFLAMMOPHARMACOLOGY (2011)
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Carol Kilkenny et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody
N. Pullen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-alpha(4)beta(7) Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
Dulce Soler et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
High-affinity binding measurements of antibodies to cell-surface-expressed antigens
Palaniswami Rathanaswami et al.
ANALYTICAL BIOCHEMISTRY (2008)
Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
Brian G. Feagan et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
W. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Role of β7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease
Maria Apostolaki et al.
GASTROENTEROLOGY (2008)
Clearance of influenza virus from the lung depends on migratory langerin+CD11b- but not plasmacytoid dendritic cells
Corine H. GeurtsvanKessel et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Immunogenicity of protein therapeutics
Anne S. De Groot et al.
TRENDS IN IMMUNOLOGY (2007)
Immunogenicity of protein therapeutics and the interplay between tolerance and antibody responses
Mario D. F. S. Borbosa et al.
DRUG DISCOVERY TODAY (2007)
Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE trial
Stephan R. Targan et al.
GASTROENTEROLOGY (2007)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Immune cell migration in inflammation: present and future therapeutic targets
AD Luster et al.
NATURE IMMUNOLOGY (2005)
Natalizumab induction and maintenance therapy for Crohn's disease
WJ Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8
P Rathanaswami et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin
BG Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Targeting leukocyte integrins in human diseases
K Yonekawa et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2005)
Retinoic acid imprints gut-homing specificity on T cells
M Iwata et al.
IMMUNITY (2004)
Immunogenicity of therapeutic proteins: Clinical implications and future prospects
H Schellekens
CLINICAL THERAPEUTICS (2002)
Integrins: Bidirectional, allosteric signaling machines
RO Hynes
CELL (2002)
Homing commitment of lymphocytes activated in the human gastric and intestinal mucosa
M Quiding-Järbrink et al.
GUT (2001)